Arkadios Wealth Advisors Acquires 11,457 Shares of Halozyme Therapeutics, Inc. $HALO

Arkadios Wealth Advisors boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 277.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,589 shares of the biopharmaceutical company’s stock after purchasing an additional 11,457 shares during the quarter. Arkadios Wealth Advisors’ holdings in Halozyme Therapeutics were worth $811,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Penserra Capital Management LLC bought a new stake in Halozyme Therapeutics in the 1st quarter valued at $125,000. Redhawk Wealth Advisors Inc. grew its stake in shares of Halozyme Therapeutics by 14.8% during the second quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after purchasing an additional 4,827 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Halozyme Therapeutics by 9.9% in the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock valued at $9,776,000 after purchasing an additional 13,789 shares in the last quarter. Shelton Wealth Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $843,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in Halozyme Therapeutics by 78.0% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock worth $5,305,000 after buying an additional 44,700 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. This represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Nicole Labrosse sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the sale, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. The trade was a 45.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 108,227 shares of company stock valued at $7,779,595 in the last quarter. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $65.19 on Monday. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The firm has a market capitalization of $7.63 billion, a P/E ratio of 14.92, a PEG ratio of 0.35 and a beta of 1.16. The business has a 50-day moving average of $71.16 and a 200-day moving average of $62.56. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the company posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on HALO shares. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Benchmark lifted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. JMP Securities boosted their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $73.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.